What clinical trial did Biome Australia (ASX:BIO) recently launch?

Biome Australia (ASX:BIO) has commenced a multi-centre, international clinical trial for its probiotic strain, BMB18 (Lactiplantibacillus plantarum, DSM 35214). This marks the expansion of the study from a single-centre trial to a collaborative international program across two academic sites.

Why is the BMB18 clinical trial a significant milestone for Biome Australia (ASX:BIO)?

The trial is highly anticipated because BMB18 represents Biome Australia’s very first wholly proprietary probiotic strain. Progressing a proprietary strain into clinical testing enhances the company's intellectual property portfolio and long-term product pipeline.

Which academic institutions are participating in the Biome Australia (ASX:BIO) clinical trial?

The international study is being conducted concurrently across two main academic sites. These are La Trobe University in Melbourne, Australia, and Harokopio University of Athens (HUA) in Greece.

Who is leading the European arm of Biome Australia’s (ASX:BIO) clinical trial?

The Greek arm of the trial at Harokopio University of Athens is led by Professor George Moschonis, a professor of human nutrition at the institution. This concurrent dual-site activation marks the first time this second-site addition has been publicly disclosed to the market.

What operational milestones has Biome Australia (ASX:BIO) completed ahead of participant recruitment?

Biome Australia has executed all site agreements, secured ethics approvals at both international centres, and completed the manufacturing, release, and delivery of the clinical trial product. These steps clear the operational hurdles required to safely begin patient dosing.

Image for illustrative purposes only. Not a real photo.

Biome launches international BMB18 probiotic clinical trial

Written by Heidi Cuthbert Published May. 27 2026Last Updated May. 27 2026

Biome Australia (ASX:BIO) has launched its multi-centre, international clinical trial for BMB18 (Lactiplantibacillus plantarum, DSM 35214).

The milestone marks an expansion from a single-centre study to a collaborative international programme spanning two major academic sites: La Trobe University in Melbourne, Australia, and Harokopio University of Athens in Greece.

The study utilises a rigorous three-arm, double-blind, placebo-controlled protocol designed to evaluate 240 participants over a six-week intervention period, followed by a two-week follow-up.

Researchers will test two distinct dosage levels of BMB18 against a placebo.

The trial is highly anticipated as BMB18 represents Biome's very first wholly proprietary probiotic strain.

All site agreements have been executed, ethics approvals are fully secured at both centres, and the clinical trial product has been manufactured, released, and successfully delivered.

Participant recruitment is commencing this week, aligning precisely with the Q4 FY26 timeline previously disclosed by the company on April 27.

The addition of the Athenian site brings substantial academic prestige to the study.

HUA is currently ranked second overall in Greece and claims the top spot nationally for research quality in the Times Higher Education World University Rankings 2026.

The Greek arm of the trial will be led by the esteemed Professor George Moschonis, a professor of human nutrition at HUA.